AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Oxandrolone in Girls with Turner's Syndrome
Twenty‐six one‐year treatment periods on ox and rolone ( 0.1 mg/kg/day ) were studied in 20 patients with Turner 's syndrome . Control patients with Turner 's syndrome were matched by using the following criteria : difference in bone age being not greater than 0.S years and difference in the Bayley‐Pinneau height prediction not greater than 3 cm . Height and height velocity were compared with st and ards of girls with Turner 's syndrome ( 10 ) and expressed in st and ard deviation scores ( SDS ) . On ox and rolone  height velocity increased significantly from −0.3 SDS to + 3.0 SDS . The increase in height velocity was negatively correlated to the bone age at onset of treatment ( r= 0.62 , p<0.01 ) . Height SDS improved by 0.45 SDS in the treated patients whereas it did not change in the control patients . The bone age velocity during the treatment period ( including a six‐month period after treatment ) was 0.75 year/year in the treated , compared to 0.66 year/year in the control patients ( NS ) . 15 of the 20 patients have reached final height . The difference in final height minus predicted height ( Bayley‐Pinneau ) at onset of treatment was taken as a measure of “ gain in final height ” . Seven of those ( mean bone age 12.1 years at onset of treatment ) were treated for one year only and had – compared to the matched controls – a mean net gain in final height of 2.5 cm ( NS ) . Eight patients ( mean bone age 10.1 years at onset of treatment ) were treated for two one‐year periods and had a significant mean net gain in final height of 5.2 cm . Height predictions calculated by the method of Lenko ( 14 ) gave an identical mean net gain in final height ( 5.1 cm
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .